JPRN-UMIN000018658已完成1 期
Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination - Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions (such as pulmonary fibrosis, active infection, uncontrollable heart disease, uncontrollable diabetes mellitus, history of severe drug allergy).
研究者
相似试验
已完成
2 期
Phase II study of intravenous and intraperitoneal paclitaxel combined with S-1 for gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000002850Department of Surgical Oncology, The University of Tokyo56
招募中
1 期
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
已完成
2 期
Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites.Advanced biliary tract cancer with carcinomatous ascitesJPRN-UMIN000007520The University of Tokyo30
已完成
不适用
Phase 1 clinical study of multiple intravenous doses of TRM-1106 in healthy Japanese adult meHealthy male subjectsJPRN-UMIN000005922Terumo Corporation20
已完成
2 期
The efficacy and the safety of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced pancreatic cancer with carcinomatous ascites.Advanced pancreatic cancer with carcinomatous ascites.JPRN-UMIN000005306The University of Tokyo30